StockNews.com Begins Coverage on Navidea Biopharmaceuticals (NYSE:NAVB)

Equities research analysts at StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB) in a research report issued on Wednesday. The firm set a “sell” rating on the stock.

Navidea Biopharmaceuticals Price Performance

Shares of Navidea Biopharmaceuticals stock opened at $0.00 on Wednesday. Navidea Biopharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $0.13. The company has a market capitalization of $100,084.00, a P/E ratio of -0.02 and a beta of 1.46.

Navidea Biopharmaceuticals Company Profile

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.